Immunohistochemical and molecular markers, for example, proliferating cell nuclear antigen, B-cell lymphoma 2, cyclin-dependent kinase 4, p53 and mouse double minute 2 homolog also allow accurate discrimination between benign and malignant smooth muscle tumors (32). This evidence concerns the gene CDK4 and smooth muscle tumor.